Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.03 USD | +0.86% | -7.09% | +72.57% |
Business Summary
Number of employees: 557
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Autologous Tumor Infiltrating Lymphocytes
100.0
%
| 0 | nan % | 1 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 1 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 16-09-29 |
Director of Finance/CFO | 51 | 20-12-13 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Chief Tech/Sci/R&D Officer | 51 | 19-07-17 | |
Igor Bilinsky
COO | Chief Operating Officer | 51 | 21-03-14 |
Merrill McPeak
BRD | Director/Board Member | 88 | 11-07-19 |
Sara Pellegrino
IRC | Investor Relations Contact | - | - |
Tracy Winton
HRO | Human Resources Officer | - | 20-03-31 |
Raj K. Puri
PRN | Corporate Officer/Principal | - | 22-02-28 |
Jim Ziegler
PRN | Corporate Officer/Principal | - | 20-01-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 11-07-19 |
Director/Board Member | 56 | 16-06-06 | |
Michael Weiser
BRD | Director/Board Member | 61 | 18-03-14 |
Wendy Yarno
BRD | Director/Board Member | 68 | 23-04-17 |
Ryan Maynard
BRD | Director/Board Member | 54 | 15-02-15 |
Iain Dukes
CHM | Chairman | 65 | 16-05-31 |
Director/Board Member | 52 | 19-06-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 2,842,158 | 0 | 0 | 87.06 % |
Stock B | 0 | 194 | 0 | 0 | |
Stock C | 1 | 278,847,679 | 242,755,910 ( 87.06 %) | 0 |
Company contact information
Iovance Biotherapeutics, Inc.
825 Industrial Road Suite 400
94070, San Carlos
+650 260 7120
http://www.iovance.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.57% | 3.89B | |
-20.44% | 10.48B | |
-6.29% | 2.47B | |
-35.49% | 2.16B | |
-21.56% | 1.58B | |
+21.53% | 1.02B | |
+5.46% | 845M | |
-17.58% | 525M | |
-35.10% | 470M | |
+10.80% | 257M |
- Stock
- Equities
- Stock Iovance Biotherapeutics, Inc. - Nasdaq
- Company Iovance Biotherapeutics, Inc.